Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis
In recent years, nerve growth factor (NGF) and the NGF receptor have become potential therapeutic targets in the treatment of acute and chronic pain states. NGF is a neurotrophin involved in regulating the function of sensory and sympathetic neurons during development. Numerous pain states have been...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2018-01-01
|
| Series: | Journal of Anaesthesiology Clinical Pharmacology |
| Subjects: | |
| Online Access: | http://www.joacp.org/article.asp?issn=0970-9185;year=2018;volume=34;issue=1;spage=111;epage=116;aulast=Patel |
| _version_ | 1818328295332118528 |
|---|---|
| author | Mona K Patel Alan D Kaye Richard D Urman |
| author_facet | Mona K Patel Alan D Kaye Richard D Urman |
| author_sort | Mona K Patel |
| collection | DOAJ |
| description | In recent years, nerve growth factor (NGF) and the NGF receptor have become potential therapeutic targets in the treatment of acute and chronic pain states. NGF is a neurotrophin involved in regulating the function of sensory and sympathetic neurons during development. Numerous pain states have been linked to elevated levels of NGF and its role in increasing the perception of pain. Tanezumab, a recombinant humanized monoclonal antibody (IgG), was developed to target NGF, binding both circulating and local tissue NGF preventing interaction with the tropomyosin-related kinase-A and p75 receptors. Recent clinical studies with tanezumab in different patient populations to date, including osteoarthritis, low back pain, and diabetic peripheral neuropathy, demonstrate efficacy with few side effects, including transient arthralgias, paresthesias, hypoesthesia, and rarely, osteonecrosis. Anti-NGF antibodies are a novel therapy in pain management and have shown promise in the treatment of certain pain conditions, which at present are poorly treated. Tanezumab offers an exciting new class of analgesics that has the potential to change the treatment of pain. |
| first_indexed | 2024-12-13T12:29:54Z |
| format | Article |
| id | doaj.art-f6f74f082254495694c03351acfadf3e |
| institution | Directory Open Access Journal |
| issn | 0970-9185 |
| language | English |
| last_indexed | 2024-12-13T12:29:54Z |
| publishDate | 2018-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Anaesthesiology Clinical Pharmacology |
| spelling | doaj.art-f6f74f082254495694c03351acfadf3e2022-12-21T23:46:05ZengWolters Kluwer Medknow PublicationsJournal of Anaesthesiology Clinical Pharmacology0970-91852018-01-0134111111610.4103/joacp.JOACP_389_15Tanezumab: Therapy targeting nerve growth factor in pain pathogenesisMona K PatelAlan D KayeRichard D UrmanIn recent years, nerve growth factor (NGF) and the NGF receptor have become potential therapeutic targets in the treatment of acute and chronic pain states. NGF is a neurotrophin involved in regulating the function of sensory and sympathetic neurons during development. Numerous pain states have been linked to elevated levels of NGF and its role in increasing the perception of pain. Tanezumab, a recombinant humanized monoclonal antibody (IgG), was developed to target NGF, binding both circulating and local tissue NGF preventing interaction with the tropomyosin-related kinase-A and p75 receptors. Recent clinical studies with tanezumab in different patient populations to date, including osteoarthritis, low back pain, and diabetic peripheral neuropathy, demonstrate efficacy with few side effects, including transient arthralgias, paresthesias, hypoesthesia, and rarely, osteonecrosis. Anti-NGF antibodies are a novel therapy in pain management and have shown promise in the treatment of certain pain conditions, which at present are poorly treated. Tanezumab offers an exciting new class of analgesics that has the potential to change the treatment of pain.http://www.joacp.org/article.asp?issn=0970-9185;year=2018;volume=34;issue=1;spage=111;epage=116;aulast=PatelMonoclonal antibodynerve growth factorneuropathic paintanezumabtropomyosin-related kinase |
| spellingShingle | Mona K Patel Alan D Kaye Richard D Urman Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis Journal of Anaesthesiology Clinical Pharmacology Monoclonal antibody nerve growth factor neuropathic pain tanezumab tropomyosin-related kinase |
| title | Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis |
| title_full | Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis |
| title_fullStr | Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis |
| title_full_unstemmed | Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis |
| title_short | Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis |
| title_sort | tanezumab therapy targeting nerve growth factor in pain pathogenesis |
| topic | Monoclonal antibody nerve growth factor neuropathic pain tanezumab tropomyosin-related kinase |
| url | http://www.joacp.org/article.asp?issn=0970-9185;year=2018;volume=34;issue=1;spage=111;epage=116;aulast=Patel |
| work_keys_str_mv | AT monakpatel tanezumabtherapytargetingnervegrowthfactorinpainpathogenesis AT alandkaye tanezumabtherapytargetingnervegrowthfactorinpainpathogenesis AT richarddurman tanezumabtherapytargetingnervegrowthfactorinpainpathogenesis |